Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
NCT07653477 on ClinicalTrials.gov · last registry update 2026-06-17
An unusually large phase 3: 956 participants, more than double the 424 typical for the stage. Due to report 29 February 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: HbA1c. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 956
- Started
- 2026-07-30
- Primary completion
- 2028-02-29 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
HbA1c
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.